Navigation Links
Helix BioPharma Announces $13.5 Million Private Placement
Date:9/3/2009

AURORA, Ontario, Sept. 4 /PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TSX, FSE: "HBP" / OTCQX: "HXBPF") today announced that it has accepted subscriptions for the purchase, by way of private placement, of a total of 6,625,000 units at $2.05 per unit, for gross proceeds totaling CDN$13,581,250. The Company anticipates closing the private placement by September 11, 2009.

Each unit consists of one common share and one common share purchase warrant, with each common share purchase warrant entitling the holder to purchase one common share of the Company at a price of $2.87 for up to three years after the closing date of the private placement. Proceeds of the placement will be used for working capital to support the Company's expanding clinical trial initiatives.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha- 2b. Helix is listed on the TSX and FSE under the symbol "HBP" and the OTCQX International Market under the symbol "HXBPF".

    For further information contact:

    Investor & Media Relations
    Robert Flamm, Ph.D.                       Ian Stone
    Russo Partners LLC                        Russo Partners LLC
    Tel: (212) 845-4226                       Tel: (619) 814-3510
    robert.flamm@russopartnersllc.com         Fax: (619) 955-5318
    www.russopartnersllc.com                  ian.stone@russopartnersllc.com

This News R
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Helix Biopharma to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
2. Double Helix Strengthens its Strategic Pricing and Reimbursement Practice with Hire of Caryn Zieses
3. New and Updated Online Tutorials for dbGaP, GAD, and DGV from OpenHelix
4. Helix BioPharma to Present L-DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference
5. Helix BioPharma Announces Q3 2009 Financial Results and Provides Product Development Update
6. Helix BioPharma to Present at the BioFinance 2009 Conference
7. Double Helix Appoints Ann Stuchiner Vice President of US Consulting Division
8. Helix BioPharma Announces Q2 2009 Financial Results
9. Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions
10. Helix BioPharma Form 20-F Registration Statement Declared Effective by SEC
11. London-Based Double Helix Consulting Launches US Division for Strategic Pricing, Reimbursement and Market Access Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Avure Technologies celebrates a year of success and ... its fleet of high volume High Pressure Processing (HPP) systems. ... return to PackExpo this year, which is where we first ... Jeff Williams, CEO at Avure. “Sales of the new Avure ... meeting the challenges of market demand for higher throughput. We ...
(Date:10/30/2014)... 30, 2014 Isis Pharmaceuticals, Inc. (NASDAQ: ... management will present a company overview at the Nomura Biotechnology ... in Boston, MA. A ... "Investors & Media" section of the Company,s website, www.isispharm.com ... within 48 hours and will be archived for a limited ...
(Date:10/30/2014)... RIDGE, N.J. , Oct. 30, 2014  Regado ... that it will hold a conference call and live ... a.m. EST to discuss its third quarter 2014 financial ... the conference call by dialing (888) 347-1165 for domestic ... call will be webcast live under the investor relations ...
(Date:10/30/2014)... (Oct. 29, 2014) – The severe flooding that devastated ... been less destructive if the bridges, roads and other ... new study from the University of Colorado Denver. , ... infrastructure," said Jimmy Kim, PhD, associate professor of structural ... Applied Science and lead author the study. "There is ...
Breaking Biology Technology:In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2Regado Biosciences to Provide Third Quarter 2014 Financial Results 2CU Denver study says upgrading infrastructure could reduce flood damage 2
... DIEGO, Aug. 21 NovaRx Corporation announced ... III clinical trial of,Lucanix(R) (belagenpumatucel-L) in the ... The first patient enrolled in the study ... principal investigator at the University,of California, San ...
... Arpida Ltd.,(SWX: ARPN) today announced that the ... its Marketing Authorisation Application (MAA) for,intravenous iclaprim. ... in,the European Union for the treatment of ... is a hospital antibiotic drug candidate with,potent ...
... iron are the basis for much of mankind,s technology, ... this week,s issue of the journal Nature ... and industrial researchers from the UK, USA and Lesotho, ... small amount of another common metal, manganese, to create ...
Cached Biology Technology:NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients 2NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients 3NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients 4Arpida's iclaprim MAA Accepted for Review by EMEA 2Arpida's iclaprim MAA Accepted for Review by EMEA 3Creating unconventional metals 2
(Date:10/31/2014)... out of a nagging mystery about the development of animal ... why animal species didn,t flourish sooner, once sufficient oxygen covered ... of the Proterozoic period, about 800 million years ago — ... researchers think there also was plenty of oxygen? , Well, ... , In a study published Oct. 30 in Science ...
(Date:10/31/2014)... green space in cities is good for attracting species, but ... environments, a University of Iowa study has found. , The ... in Iowa, and recorded the abundance of two insects that ... of the trees, black cherry and black walnut, they didn,t ... fruit flies that feed on the walnuts and black cherries ...
(Date:10/31/2014)... uncovered key steps involved in programmed cell death, offering ... cancers and neurodegenerative diseases. , The research teams ... to discover the three-dimensional structure of a key cell ... in how it causes cell death. Their studies were ... Proceedings of the National Academy of Sciences ...
Breaking Biology News(10 mins):Lack of oxygen delayed the rise of animals on Earth 2Green spaces don't ensure biodiversity in urban areas 2A matter of life and death: Cell death proteins key to fighting disease 2
... are developing a cost-effective electronic monitoring system that will ... ecosystems by allowing users to track water-quality data from ... a National Science Foundation (NSF) grant. "Our goal ... environmental conditions in the Chesapeake Bay, the sounds of ...
... to help the government cut through red tape and roll ... This week, the university,s Durham Energy ... meet with the Department of Energy & Climate Change to ... on Wednesday November 3rd will also be attended by Ofgem ...
... Calif., Nov. 1, 2010 General Manifolds LLC, a ... that the United States Patent and Trademark Office has ... method for simulating functions within the cerebral cortex of ... a broad range of applications from artificial intelligence to ...
Cached Biology News:Researchers developing real-time electronic monitoring for coastal waters 2Durham Energy Institute to advise government on green technology 2General Manifolds LLC Announces Issuance of US Patent in Computational Neuroscience 2
... Service The Human Genetic Cell Bank ... (EBV) immortalisation of human peripheral blood lymphocytes ... cell lines (LCLs). These cell lines are ... source of genomic DNA and RNA. ...
... Extract Protein Array Kit is designed for ... The expression of a protein in an ... antibody. When the antibody binds the protein, ... chemiluminescent or fluorescent signal created by directly ...
Glycerol-based mounting medium for immunofluorescence microscopy. Formulated to retard photobleaching of fluorochromes such as fluorescein and rhodamine. Product can also be used as a diluent for fl...
... is specifically formulated for mounting tissue specimens, ... stained with immunohistochemical methods for viewing by ... with chromogens, such as AEC, that are ... dries completely when slides are cover-slipped forming ...
Biology Products: